NCT00578916View on ClinicalTrials.gov

Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Cancer
Interventions
DRUG

EVRI (BMS-690514)

Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay

Trial Locations (1)

487 2401

Local Institution, Allschwil

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY